Intensity of FDG uptake is not everything: Synchronous liposarcoma and fibrous dysplasia in the same patient on FDG PET-CT imaging

Clinical Nuclear Medicine

Volumn 33, Issue 7, 2008, Pages 455-458

  Charest, Mathieu ^a   Singnurkar, Amit ^b   Hickeson, Marc ^b   Novales, J A ^b   Derbekyan, Vilma ^b  

^a Lakeshore General Hospital   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

FDG; Fibrous dysplasia; Liposarcoma; PET CT; Sarcoma

Indexed keywords

FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; BENIGN TUMOR; CANCER DIAGNOSIS; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FIBROUS DYSPLASIA; HUMAN; IMAGE ANALYSIS; LIPOSARCOMA; MALE; MALIGNANT NEOPLASTIC DISEASE; PREOPERATIVE EVALUATION; TIBIA; COMPUTER ASSISTED TOMOGRAPHY; INCIDENTAL FINDING; METHODOLOGY; MIDDLE AGED; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SARCOMA; SECOND CANCER; SOFT TISSUE TUMOR; WHOLE BODY IMAGING;

DIAGNOSTIC IMAGING; FIBROUS DYSPLASIA OF BONE; FLUORODEOXYGLUCOSE F18; HUMANS; INCIDENTAL FINDINGS; LIPOSARCOMA; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; SARCOMA; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING;

EID: 52249092242     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31817793bb     Document Type: Article

References (10)

1. Brenner W, Eary JF, Hwang W, et al. Risk assessment in liposarcoma patients based on FDG PET imaging. Eur J Nucl Med Mol Imaging. 2006;33:1290-1295.
2. Schwarzbach MH, Hinz U, Dimitrakopoulou-Strauss A, et al. Prognostic significance of preoperative [18-F] fluorodeoxyglucose positron emission tomography imaging in patients with resectable soft tissue sarcomas. Ann Surg. 2005;241:286-294.
3. Bastiaannet E, Groen H, Jager PL, et al. The value of FDG-PET in the detection, grading and response to therapy of soft tissue and bone sarcomas; a systematic review and meta-analysis. Cancer Treat Rev. 2004;30:83-101.
4. Eary JF, O'Sullivan F, Powitan Y, et al. Sarcoma tumor FDG uptake measured by PET and patient outcome: a retrospective analysis. Eur J Nucl Med Mol Imaging. 2002;29:1149-1154.
5. Folpe AL, Lyles RH, Sprouse JT, et al. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6:1279-1287.
6. Strauss LG. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients. Eur J Nucl Med Mol Imaging. 1996;23:1409-1415.
7. Von Falck C, Rosenthal H, Laenger F, et al. Avid uptake of 18F-FDG in fibrous dysplasia can mimic skeletal involvement in Hodgkin's disease. Eur J Nucl Med Mol Imaging. 2008;35:223.
8. Kao CH, Sun SS, Shen YY, et al. Misdiagnosis of multiple bone metastases due to increased FDG uptake in polyostotic fibrous dysplasia. Clin Nucl Med. 2007;32:409-410.
9. Stegger L, Juergens KU, Kliesch S, et al. Unexpected finding of elevated glucose uptake in fibrous dysplasia mimicking malignancy: contradicting metabolism and morphology in combined PET/CT. Eur Radiol. 2007;17:1784-1786.
10. Strobel K, Bode B, Lardinois D, et al. PET-positive fibrous dysplasia-a potentially misleading incidental finding in a patient with intimal sarcoma of the pulmonary artery. Skeletal Radiol. 2007;36:S24-S28.